Celebrating a Shared Milestone
Recently, BioDlink and Lepu Biopharma marked an important achievement in the biopharmaceutical industry with the launch of MEIYOUHENG®, the world’s first EGFR-targeting Antibody-Drug Conjugate (ADC). This notable partnership highlights the companies' dedication and collaboration over the past two years.
Demonstrating Robust Capabilities
This successful launch is more than just a technological milestone; it showcases the robust capabilities of BioDlink. Throughout the partnership, all technology transfers and GMP manufacturing batches were completed on the first attempt, underscoring BioDlink's high standards and quality assurance systems.
A Milestone for the Biopharmaceutical Ecosystem
MEIYOUHENG® stands out as the first ADC fully manufactured by a Contract Development and Manufacturing Organization (CDMO) to be commercially available, signaling a new level of sophistication in the biopharmaceutical ecosystem. This instance reflects a significant evolution in the local industry, enhancing its reputation on a global stage.
Operational Excellence That Sets a New Benchmark
Senior leaders and project teams from both companies met at BioDlink's headquarters to celebrate this remarkable success. The launch not only represents deep scientific collaboration but also underscores a disciplined approach to executing complex biologics projects effectively.
A Fully Integrated CDMO Success Story
The successful approval and launch of MEIYOUHENG® affirm BioDlink's full-spectrum capabilities as a CDMO. These capabilities include technology transfer, critical clinical production, and comprehensive support during the approval processes led by the National Medical Products Administration (NMPA). Remarkably, the technology transfer was achieved in less than three months, and the pivotal production qualification (PPQ) was finalized in under eleven months, showcasing efficiency and meticulous planning.
Voices from Leadership
Dr. Jian Zhang, Chief Operating Officer at BioDlink, expressed pride in the collaboration, stating, "We are thrilled to have contributed to the development and launch of the world's first approved EGFR-Targeting ADC drug. This achievement highlights our ongoing commitment to quality and innovation within the industry."
Similarly, Dr. Ziye Sui, Executive Director and CEO of Lepu Biopharma, praised the collaboration, saying, "BioDlink has demonstrated exceptional technical expertise and commitment in our partnership, which has been vital for the successful launch of MEIYOUHENG®. We eagerly anticipate continuing our partnership to bring more innovative therapies to patients worldwide."
Looking to the Future
As both companies continue to innovate, BioDlink plans to utilize its integrated CDMO platform to support global partners in speeding up the development and commercialization of various biologics. This includes advancements in monoclonal antibodies, biosimilars, and more complex molecules such as ADCs.
About BioDlink Biopharm Co., Ltd.
BioDlink is recognized as a leading global CDMO focused on biologics and bioconjugates. With headquarters in Suzhou and additional centers in Shanghai and Beijing, it offers a comprehensive range of services that span early research and development to commercial manufacturing. BioDlink's cutting-edge technologies like BDKcell® for cell line development further enhance its ability to streamline production and ensure quality across all developments.
About Lepu Biopharma
Lepu Biopharma is dedicated to developing promising oncology therapeutics, particularly in targeted therapies and immunotherapy. With a strong foundation in China and a global perspective, Lepu Biopharma is committed to innovation in ADC technology and the completion of drug commercialization.
Frequently Asked Questions
What is MEIYOUHENG®?
MEIYOUHENG® is the world’s first EGFR-targeting ADC developed and launched by BioDlink and Lepu Biopharma, representing a significant advancement in biopharmaceutical innovation.
What roles did BioDlink and Lepu Biopharma play in the drug's development?
BioDlink provided end-to-end CDMO services, including technology transfer and clinical production, while Lepu Biopharma focused on the innovation and creation of the drug itself.
What impact does this launch have on the biopharmaceutical ecosystem?
The launch of MEIYOUHENG® sets a new standard for the maturity and sophistication of the biopharmaceutical industry, particularly within the Asian market.
What advantages does BioDlink offer to its partners?
BioDlink offers a fully integrated CDMO platform, advanced technologies, and a commitment to quality, improving efficiency and reducing costs for its partners.
What are the future plans for BioDlink?
BioDlink aims to expand its support for global partners in developing a diverse range of biologics, leveraging its cutting-edge technology and operational excellence.
